Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs
The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.
You may also be interested in...
Hopes were high for an expanded approval of Raxone but the CHMP's negative opinion has left the Swiss company's stock battered and bruised.
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
How will the confirmatory trial necessary to convert accelerated approval to full approval affect sales given the small size of the target population?